Viking Therapeutics (VKTX) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to -$157.7 million.
- Viking Therapeutics' Net Income towards Common Stockholders fell 34556.42% to -$157.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$359.6 million, marking a year-over-year decrease of 22700.01%. This contributed to the annual value of -$359.6 million for FY2025, which is 22700.01% down from last year.
- Viking Therapeutics' Net Income towards Common Stockholders amounted to -$157.7 million in Q4 2025, which was down 34556.42% from -$90.8 million recorded in Q3 2025.
- Viking Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$12.4 million for Q4 2021, and its period low was -$157.7 million during Q4 2025.
- For the 5-year period, Viking Therapeutics' Net Income towards Common Stockholders averaged around -$34.0 million, with its median value being -$20.9 million (2022).
- In the last 5 years, Viking Therapeutics' Net Income towards Common Stockholders plummeted by 1044.42% in 2023 and then tumbled by 34556.42% in 2025.
- Viking Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then crashed by 44.0% to -$35.4 million in 2024, then plummeted by 345.56% to -$157.7 million in 2025.
- Its Net Income towards Common Stockholders was -$157.7 million in Q4 2025, compared to -$90.8 million in Q3 2025 and -$65.5 million in Q2 2025.